{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:48:51Z","timestamp":1791582531375,"version":"4.3.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.82302029"],"award-info":[{"award-number":["No.82302029"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82572070"],"award-info":[{"award-number":["No. 82572070"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012542","name":"Sichuan Provincial Science and Technology Support Program","doi-asserted-by":"publisher","award":["No.2024YFFK0062"],"award-info":[{"award-number":["No.2024YFFK0062"]}],"id":[{"id":"10.13039\/100012542","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"DOI":"10.1007\/s12026-026-09828-5","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:51:07Z","timestamp":1788853867000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety profiles of CAR-T cell therapy in systematic autoimmune diseases: a systematic review and analysis"],"prefix":"10.1007","volume":"74","author":[{"given":"Yan","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qibing","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"issue":"11","key":"9828_CR1","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1136\/ard-2024-225727","volume":"83","author":"G Schett","year":"2024","unstructured":"Schett G, Nagy G, Kr\u00f6nke G, Mielenz D. B-cell depletion in autoimmune diseases. Ann Rheum Dis. 2024;83(11):1409\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"9828_CR2","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","volume":"24","author":"JB Chung","year":"2024","unstructured":"Chung JB, Brudno JN, Borie D, Kochenderfer JN. Chimeric antigen receptor T cell therapy for autoimmune disease. Nat Rev Immunol. 2024;24(11):830\u201345.","journal-title":"Nat Rev Immunol"},{"issue":"7971","key":"9828_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker DJ, Arany Z, Baur JA, Epstein JA, June CH. CAR T therapy beyond cancer: the evolution of a living drug. Nature. 2023;619(7971):707\u201315.","journal-title":"Nature"},{"issue":"2","key":"9828_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","volume":"18","author":"KL Chohan","year":"2023","unstructured":"Chohan KL, Siegler EL, Kenderian SS. CAR-T cell therapy: the efficacy and toxicity balance. Curr Hematol Malig Rep. 2023;18(2):9\u201318.","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"9828_CR5","doi-asserted-by":"publisher","first-page":"77.e1","DOI":"10.1016\/j.jtct.2023.10.017","volume":"30","author":"CA Jacobson","year":"2024","unstructured":"Jacobson CA, Munoz J, Sun F, Kanters S, Limbrick-Oldfield EH, Spooner C, et al. Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis. Transplant Cell Ther. 2024;30(1):77.e1-77.e15.","journal-title":"Transplant Cell Ther"},{"key":"9828_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152786","volume":"74","author":"A Nordmann-Gomes","year":"2025","unstructured":"Nordmann-Gomes A, Khalili L, Tang W, Geraldino-Pardilla L, Gartshteyn Y, Clancy R, et al. CAR T-cell therapy in SLE: A systematic review. Semin Arthritis Rheum. 2025;74:152786.","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"9828_CR7","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1182\/blood.2025028375","volume":"146","author":"F M\u00fcller","year":"2025","unstructured":"M\u00fcller F, Schwingen NR, Hagen M, Scholz JK, Aigner M, Wirsching A, et al. Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma. Blood. 2025;146(9):1088\u201395.","journal-title":"Blood"},{"issue":"15","key":"9828_CR8","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1056\/NEJMc2509522","volume":"393","author":"Q Wang","year":"2025","unstructured":"Wang Q, Xiao ZX, Zheng X, Wang G, Yang L, Shi L, et al. In vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus. N Engl J Med. 2025;393(15):1542\u20134.","journal-title":"N Engl J Med"},{"key":"9828_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103229","volume":"83","author":"J Shu","year":"2025","unstructured":"Shu J, Xie W, Mei C, Ren A, Ke S, Ma M, et al. Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial. EClinicalMedicine. 2025;83:103229.","journal-title":"EClinicalMedicine"},{"issue":"11","key":"9828_CR10","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1038\/s41591-025-03937-8","volume":"31","author":"J Feng","year":"2025","unstructured":"Feng J, Huo D, Hong R, Jin X, Cao H, Shao M, et al. Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat Med. 2025;31(11):3725\u201336.","journal-title":"Nat Med"},{"issue":"11","key":"9828_CR11","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1038\/s41591-025-03899-x","volume":"31","author":"X Wang","year":"2025","unstructured":"Wang X, Zhang Y, Wang H, Wu X, He C, Lin S, et al. Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat Med. 2025;31(11):3713\u201324.","journal-title":"Nat Med"},{"issue":"10","key":"9828_CR12","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A, M\u00fcller F, Mougiakakos D, B\u00f6ltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022;28(10):2124\u201332.","journal-title":"Nat Med"},{"issue":"6","key":"9828_CR13","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1007\/s12015-025-10923-7","volume":"21","author":"M Wang","year":"2025","unstructured":"Wang M, DeStefano VM, Ding L, Hong M, Zeng R, Wada M, et al. Validation of BCMA-CD19 compound CAR-T therapy in SLE overlap syndrome: over 1.5-year follow-up. Stem Cell Rev Rep. 2025;21(6):1750\u20139.","journal-title":"Stem Cell Rev Rep"},{"issue":"6","key":"9828_CR14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2315990121","volume":"121","author":"C Qin","year":"2024","unstructured":"Qin C, Dong MH, Zhou LQ, Wang W, Cai SB, You YF, et al. Single-cell analysis of refractory anti-SRP necrotizing myopathy treated with anti-BCMA CAR-T cell therapy. Proc Natl Acad Sci U S A. 2024;121(6):e2315990121.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"9828_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ekir.2025.10.008","volume":"11","author":"Y Mao","year":"2025","unstructured":"Mao Y, Shen W, Shen J, Zhang C, An K, Tang Y, et al. Bicistronic-CD19\/22 chimeric antigen receptor T-cell therapy for childhood refractory lupus nephritis. Kidney International Reports\u00ae. 2025;11(1):53\u201361.","journal-title":"Kidney International Reports\u00ae"},{"issue":"7","key":"9828_CR16","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S2213-2600(25)00159-6","volume":"13","author":"W Merkt","year":"2025","unstructured":"Merkt W, R\u00f6hrich M, Mavriopoulou E, St\u00fctz AN, Distler JHW, Schmitt A, et al. Persisting CD19.CAR-T cells in combination with nintedanib: clinical response in a patient with systemic sclerosis-associated pulmonary fibrosis after 2 years. Lancet Respir Med. 2025;13(7):651\u20134.","journal-title":"Lancet Respir Med"},{"issue":"8","key":"9828_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, V\u00f6lkl S, et al. CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med. 2024;390(8):687\u2013700.","journal-title":"N Engl J Med"},{"issue":"4","key":"9828_CR18","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1056\/NEJMc2403743","volume":"391","author":"M Li","year":"2024","unstructured":"Li M, Zhang Y, Jiang N, Ning C, Wang Q, Xu D, et al. Anti-CD19 CAR T cells in refractory immune thrombocytopenia of SLE. N Engl J Med. 2024;391(4):376\u20138.","journal-title":"N Engl J Med"},{"issue":"6","key":"9828_CR19","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, Kr\u00f6nke G, V\u00f6lkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med. 2021;385(6):567\u20139.","journal-title":"N Engl J Med"},{"issue":"2","key":"9828_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2025-001742","volume":"12","author":"JM Gerber","year":"2025","unstructured":"Gerber JM, Dehdashtian E, Hu G, Gregoire C, Borie D, Bindal P, et al. Successful autologous CD19 CAR T cell therapy following severe lupus flare during immunosuppressive washout in refractory lupus nephritis. Lupus Sci Med. 2025;12(2):e001742.","journal-title":"Lupus Sci Med"},{"issue":"9","key":"9828_CR21","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1093\/rheumatology\/keaf190","volume":"64","author":"I Haase","year":"2025","unstructured":"Haase I, Richter J, Holzer MT, Fehse B, Ruffer N, Seibel J, et al. A novel approach to refractory idiopathic inflammatory myopathy: CD19 CAR T-cell therapy-case report and literature review. Rheumatology (Oxford). 2025;64(9):5101\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"9828_CR22","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1093\/rheumatology\/keaf077","volume":"64","author":"FN Albach","year":"2025","unstructured":"Albach FN, Minopoulou I, Wilhelm A, Biesen R, Kleyer A, Wiebe E, et al. Targeting autoimmunity with CD19-CAR T-cell therapy: efficacy and seroconversion in diffuse systemic sclerosis and rheumatoid arthritis. Rheumatology (Oxford). 2025;64(6):4075\u20137.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"9828_CR23","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","volume":"63","author":"J Taubmann","year":"2024","unstructured":"Taubmann J, Knitza J, M\u00fcller F, V\u00f6lkl S, Aigner M, Kleyer A, et al. Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies. Rheumatology (Oxford). 2024;63(1):e12-4.","journal-title":"Rheumatology (Oxford)"},{"key":"9828_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1645304","volume":"16","author":"X Liu","year":"2025","unstructured":"Liu X, Zhu W, Su N, Ma Y, Wang F, Xu J, et al. Case report: remission of a patient with complex combination of autoimmune diseases by anti-CD19 CAR-T cell therapy. Front Immunol. 2025;16:1645304.","journal-title":"Front Immunol"},{"issue":"11","key":"9828_CR25","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1136\/ard-2024-226017","volume":"83","author":"A Haghikia","year":"2024","unstructured":"Haghikia A, Hegelmaier T, Wolleschak D, B\u00f6ttcher M, Pappa V, Motte J, et al. Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis. Ann Rheum Dis. 2024;83(11):1597\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"24","key":"9828_CR26","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","volume":"329","author":"AC Pecher","year":"2023","unstructured":"Pecher AC, Hensen L, Klein R, Schairer R, Lutz K, Atar D, et al. CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA. 2023;329(24):2154\u201362.","journal-title":"JAMA"},{"issue":"11","key":"9828_CR27","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.1016\/j.ymthe.2024.09.009","volume":"32","author":"J Volkov","year":"2024","unstructured":"Volkov J, Nunez D, Mozaffar T, Stadanlick J, Werner M, Vorndran Z, et al. Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I\/II trial. Mol Ther. 2024;32(11):3821\u20138.","journal-title":"Mol Ther"},{"issue":"10","key":"9828_CR28","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/ard-2024-225785","volume":"83","author":"W Wang","year":"2024","unstructured":"Wang W, He S, Zhang W, Zhang H, DeStefano VM, Wada M, et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann Rheum Dis. 2024;83(10):1304\u201314.","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"9828_CR29","first-page":"2001","volume":"43","author":"X Zhao","year":"2025","unstructured":"Zhao X, Zhang L, Zhang X, Liu X, Zhang Y, Liu Y, et al. Anti-CD19 chimeric antigen receptor T cell therapy achieved rapid and sustained remission in a patient with systemic lupus erythematosus-associated refractory immune thrombocytopenia. Clin Exp Rheumatol. 2025;43(11):2001\u20132.","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"9828_CR30","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/art.42933","volume":"76","author":"R Nicolai","year":"2024","unstructured":"Nicolai R, Merli P, Moran Alvarez P, Bracaglia C, Del Bufalo F, Marasco E, et al. Autologous CD19-targeting CAR T cells in a patient with refractory juvenile dermatomyositis. Arthritis Rheumatol. 2024;76(10):1560\u20135.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"9828_CR31","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1136\/ard-2023-223952","volume":"82","author":"C Bergmann","year":"2023","unstructured":"Bergmann C, M\u00fcller F, Distler JHW, Gy\u00f6rfi AH, V\u00f6lkl S, Aigner M, et al. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rheum Dis. 2023;82(8):1117\u201320.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"9828_CR32","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1016\/j.ard.2025.01.008","volume":"84","author":"I Minopoulou","year":"2025","unstructured":"Minopoulou I, Wilhelm A, Albach F, Kleyer A, Wiebe E, Schallenberg S, et al. Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy-refractory patient with ANCA-associated vasculitis. Ann Rheum Dis. 2025;84(3):e4\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"9828_CR33","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41422-025-01128-1","volume":"35","author":"C Yang","year":"2025","unstructured":"Yang C, Sun C, Tan B, Hu C, Wan L, Wang C, et al. Allogeneic anti-CD19 CAR-T cells induce remission in refractory systemic lupus erythematosus. Cell Res. 2025;35(8):607\u20139.","journal-title":"Cell Res"},{"issue":"3","key":"9828_CR34","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41422-024-01068-2","volume":"35","author":"Y Li","year":"2025","unstructured":"Li Y, Li S, Zhao X, Sheng J, Xue L, Schett G, et al. Fourth-generation chimeric antigen receptor T-cell therapy is tolerable and efficacious in treatment-resistant rheumatoid arthritis. Cell Res. 2025;35(3):220\u20133.","journal-title":"Cell Res"},{"issue":"8","key":"9828_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100676","volume":"6","author":"A Par\u00eds-Mu\u00f1oz","year":"2025","unstructured":"Par\u00eds-Mu\u00f1oz A, Alcobendas-Rueda RM, Verd\u00fa-S\u00e1nchez C, Udaondo C, Gal\u00e1n-G\u00f3mez V, Gonz\u00e1lez-Mart\u00ednez B, et al. CD19 CAR-T cell therapy in a pediatric patient with MDA5+ dermatomyositis and rapidly progressive interstitial lung disease. Med. 2025;6(8):100676.","journal-title":"Med"},{"issue":"2","key":"9828_CR36","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","volume":"7","author":"J Auth","year":"2025","unstructured":"Auth J, M\u00fcller F, V\u00f6lkl S, Bayerl N, Distler JHW, Tur C, et al. CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series. Lancet Rheumatol. 2025;7(2):e83\u201393.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"9828_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103692","volume":"24","author":"X He","year":"2025","unstructured":"He X, Hu B, Zhang Y, Liu F, Li Q, Zheng C, et al. Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells. Autoimmun Rev. 2025;24(1):103692.","journal-title":"Autoimmun Rev"},{"key":"9828_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2025.103489","volume":"157","author":"Y Wang","year":"2025","unstructured":"Wang Y, Yang S, Yu Y, Xia P, Xie C, Zhang C, et al. Preliminary safety and efficacy of relmacabtagene autoleucel (relma-cel) in adults with moderately to severely active systemic lupus erythematosus: a phase I dose-escalation study. J Autoimmun. 2025;157:103489.","journal-title":"J Autoimmun"},{"issue":"10","key":"9828_CR39","volume":"6","author":"D Wang","year":"2025","unstructured":"Wang D, Wang X, Tan B, Wen X, Ye S, Wu Y, et al. Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission. Med (Baltimore). 2025;6(10):100749.","journal-title":"Med (Baltimore)"},{"issue":"10472","key":"9828_CR40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0140-6736(24)02504-2","volume":"405","author":"K Trautmann-Grill","year":"2025","unstructured":"Trautmann-Grill K, von Bonin M, Georgi A, Middeke JM, B\u00f6ttcher M, Meyer O, et al. Salvage treatment of multi-refractory primary immune thrombocytopenia with CD19 CAR T cells. Lancet. 2025;405(10472):25\u20138.","journal-title":"Lancet"},{"issue":"10468","key":"9828_CR41","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1016\/S0140-6736(24)02265-7","volume":"404","author":"M Hagen","year":"2024","unstructured":"Hagen M, M\u00fcller F, Wirsching A, Kharboutli S, Sp\u00f6rl S, Aigner M, et al. Treatment of CNS systemic lupus erythematosus with CD19 CAR T cells. Lancet. 2024;404(10468):2158\u201360.","journal-title":"Lancet"},{"issue":"10437","key":"9828_CR42","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","volume":"403","author":"T Krickau","year":"2024","unstructured":"Krickau T, Naumann-Bartsch N, Aigner M, Kharboutli S, Kretschmann S, Spoerl S, et al. CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis. Lancet. 2024;403(10437):1627\u201330.","journal-title":"Lancet"},{"issue":"10379","key":"9828_CR43","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","volume":"401","author":"F M\u00fcller","year":"2023","unstructured":"M\u00fcller F, Boeltz S, Knitza J, Aigner M, V\u00f6lkl S, Kharboutli S, et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet. 2023;401(10379):815\u20138.","journal-title":"Lancet"},{"issue":"18","key":"9828_CR44","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","volume":"187","author":"X Wang","year":"2024","unstructured":"Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L, et al. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell. 2024;187(18):4890-4904.e9.","journal-title":"Cell"},{"issue":"10","key":"9828_CR45","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.ard.2025.06.2128","volume":"84","author":"Z Hu","year":"2025","unstructured":"Hu Z, Cai S, Yu Y, Chen Y, Wang B, Wang D, et al. BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis. Ann Rheum Dis. 2025;84(10):1675\u201383.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"9828_CR46","first-page":"1254","volume":"110","author":"O Beyar-Katz","year":"2025","unstructured":"Beyar-Katz O, Rejeski K, Shouval R. Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategies. Haematologica. 2025;110(6):1254\u201368.","journal-title":"Haematologica"},{"issue":"11","key":"9828_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010064","volume":"12","author":"X Liang","year":"2024","unstructured":"Liang X, Wang Y, Luo B, Lin B, Lu W, Tian S, et al. Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis. J Immunother Cancer. 2024;12(11):e010064.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"9828_CR48","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2349796","volume":"56","author":"SE Willyanto","year":"2024","unstructured":"Willyanto SE, Alimsjah YA, Tanjaya K, Tuekprakhon A, Pawestri AR. Comprehensive analysis of the efficacy and safety of CAR T-cell therapy in patients with relapsed or refractory B-cell acute lymphoblastic leukaemia: a systematic review and meta-analysis. Ann Med. 2024;56(1):2349796.","journal-title":"Ann Med"},{"issue":"20","key":"9828_CR49","first-page":"2430","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood. 2023;141(20):2430\u201342.","journal-title":"Blood"},{"key":"9828_CR50","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev. 2019;34:45\u201355.","journal-title":"Blood Rev"},{"issue":"7","key":"9828_CR51","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024;21(7):501\u201321.","journal-title":"Nat Rev Clin Oncol"},{"issue":"3\u20134","key":"9828_CR52","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00281-024-01013-w","volume":"46","author":"AD Hughes","year":"2024","unstructured":"Hughes AD, Teachey DT, Diorio C. Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy. Semin Immunopathol. 2024;46(3\u20134):5.","journal-title":"Semin Immunopathol"},{"issue":"20","key":"9828_CR53","first-page":"2460","volume":"141","author":"T Jain","year":"2023","unstructured":"Jain T, Olson TS, Locke FL. How I treat cytopenias after CAR T-cell therapy. Blood. 2023;141(20):2460\u20139.","journal-title":"Blood"},{"issue":"23","key":"9828_CR54","doi-asserted-by":"publisher","first-page":"3662","DOI":"10.1111\/jcmm.17930","volume":"27","author":"Q Liu","year":"2023","unstructured":"Liu Q, Hu T, Li H, Shen Y, Wu D, Ye B. Prolonged haematologic toxicity in CAR-T-cell therapy: A review. J Cell Mol Med. 2023;27(23):3662\u201371.","journal-title":"J Cell Mol Med"},{"key":"9828_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104134","volume":"192","author":"GK Reynolds","year":"2023","unstructured":"Reynolds GK, Sim B, Spelman T, Thomas A, Longhitano A, Anderson MA, et al. Infections in haematology patients treated with CAR-T therapies: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2023;192:104134.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"9828_CR56","doi-asserted-by":"publisher","first-page":"e7372","DOI":"10.1002\/cam4.7372","volume":"13","author":"J An","year":"2024","unstructured":"An J, Zhao J, Zou P, Zhang Y, Wei J, Tian W, et al. Infections associated with CAR-T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies. Cancer Med. 2024;13(12):e7372.","journal-title":"Cancer Med"},{"issue":"1","key":"9828_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01354-9","volume":"15","author":"C Yin","year":"2022","unstructured":"Yin C, Gao J, Li G, Hu H, Zhou L, Lu S, et al. Gene and cell therapies in China: booming landscape under dual-track regulation. J Hematol Oncol. 2022;15(1):139.","journal-title":"J Hematol Oncol"},{"key":"9828_CR58","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-25-04559","author":"A Tariq","year":"2026","unstructured":"Tariq A, Kumar V, Prasad V. The U.S. Food and Drug Administration\u2019s perspective on chimeric antigen receptor T-cell therapies for autoimmune and rheumatic conditions. Ann Intern Med. 2026. https:\/\/doi.org\/10.7326\/ANNALS-25-04559.","journal-title":"Ann Intern Med"},{"key":"9828_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1466443","volume":"15","author":"X Yang","year":"2024","unstructured":"Yang X, Wang F, Yuan X, Yang B, Chen J, Cheng J, et al. Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma. Front Immunol. 2024;15:1466443.","journal-title":"Front Immunol"},{"key":"9828_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.544754","volume":"11","author":"X Xiang","year":"2020","unstructured":"Xiang X, He Q, Ou Y, Wang W, Wu Y. Efficacy and safety of CAR-modified T cell therapy in patients with relapsed or refractory multiple myeloma: a meta-analysis of prospective clinical trials. Front Pharmacol. 2020;11:544754.","journal-title":"Front Pharmacol"},{"issue":"1","key":"9828_CR61","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41571-024-00959-y","volume":"22","author":"C Diorio","year":"2025","unstructured":"Diorio C, Teachey DT, Grupp SA. Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks. Nat Rev Clin Oncol. 2025;22(1):10\u201327.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09828-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-026-09828-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09828-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:02:20Z","timestamp":1788858140000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-026-09828-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9828"],"URL":"https:\/\/doi.org\/10.1007\/s12026-026-09828-5","relation":{},"ISSN":["1559-0755"],"issn-type":[{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"19 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participant","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"104"}}